Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Harry L Messmore

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|October 26, 2005
Argatroban and lepirudin: clinical trials to clinical practiceHarry L Messmore, Jawed Fareed, Jeanine M Walenga, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|October 22, 2004
Anti-Xa and anti-IIa drugs alter international normalized ratio measurements: potential problems in the monitoring of oral anticoagulantsMahmut Tobu, Omer Iqbal, Debra Hoppensteadt, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|September 9, 2006
Thromboembolism in cancer patients: pathogenesis and treatmentMatthew Adess, Robert Eisner, Sucha Nand, et al.
Hematology/Oncology Clinics of North America|January 22, 2008
Laboratory evaluation of the antiphospholipid syndromeDebra A Hoppensteadt, Nancy Fabbrini, Rodger L Bick, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|April 26, 2007
Potential thrombogenic complications with the use of recombinant activated factor VII in combat traumaJawed Fareed, Rodger L Bick, Craig Kessler, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|December 5, 2003
Differential effects of DX-9065a, argatroban, and synthetic pentasaccharide on tissue thromboplastin inhibition test and dilute Russell's viper venom testRolandas Gerbutavicius, Omer Iqbal, Harry L Messmore, et al.
British Journal of Haematology|August 2, 2008
Rivaroxaban--an oral, direct Factor Xa inhibitor--has potential for the management of patients with heparin-induced thrombocytopeniaJeanine M Walenga, Margaret Prechel, Walter P Jeske, et al.
Molecular and Cellular Biochemistry|March 20, 2004
Differential prevalence of anti-heparin-PF4 immunoglobulin subtypes in patients treated with clivarin and heparin: implications in the HIT pathogenesisSarfraz Ahmad, Brian Untch, Sylvia Haas, et al.
Hematology/Oncology Clinics of North America|January 11, 2005
Antiplatelet agents: current drugs and future trendsHarry L Messmore, Walter P Jeske, William Wehrmacher, et al.
Thrombosis Research|August 17, 2002
Development of a non-human primate sub-clinical model of heparin-induced thrombocytopenia: platelet responses to human anti-heparin-platelet factor 4 antibodiesBrian Untch, Sarfraz Ahmad, Harry L Messmore, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|October 26, 2005
Argatroban and lepirudin: clinical trials to clinical practiceHarry L Messmore, Jawed Fareed, Jeanine M Walenga, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|October 22, 2004
Anti-Xa and anti-IIa drugs alter international normalized ratio measurements: potential problems in the monitoring of oral anticoagulantsMahmut Tobu, Omer Iqbal, Debra Hoppensteadt, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|September 9, 2006
Thromboembolism in cancer patients: pathogenesis and treatmentMatthew Adess, Robert Eisner, Sucha Nand, et al.
Hematology/Oncology Clinics of North America|January 22, 2008
Laboratory evaluation of the antiphospholipid syndromeDebra A Hoppensteadt, Nancy Fabbrini, Rodger L Bick, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|April 26, 2007
Potential thrombogenic complications with the use of recombinant activated factor VII in combat traumaJawed Fareed, Rodger L Bick, Craig Kessler, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|December 5, 2003
Differential effects of DX-9065a, argatroban, and synthetic pentasaccharide on tissue thromboplastin inhibition test and dilute Russell's viper venom testRolandas Gerbutavicius, Omer Iqbal, Harry L Messmore, et al.
British Journal of Haematology|August 2, 2008
Rivaroxaban--an oral, direct Factor Xa inhibitor--has potential for the management of patients with heparin-induced thrombocytopeniaJeanine M Walenga, Margaret Prechel, Walter P Jeske, et al.
Molecular and Cellular Biochemistry|March 20, 2004
Differential prevalence of anti-heparin-PF4 immunoglobulin subtypes in patients treated with clivarin and heparin: implications in the HIT pathogenesisSarfraz Ahmad, Brian Untch, Sylvia Haas, et al.
Hematology/Oncology Clinics of North America|January 11, 2005
Antiplatelet agents: current drugs and future trendsHarry L Messmore, Walter P Jeske, William Wehrmacher, et al.
Thrombosis Research|August 17, 2002
Development of a non-human primate sub-clinical model of heparin-induced thrombocytopenia: platelet responses to human anti-heparin-platelet factor 4 antibodiesBrian Untch, Sarfraz Ahmad, Harry L Messmore, et al.
Pageof 3